Fig. 1
HbA1c (a), weight (b) and (c) insulin dose trajectories with IDegLira and ICT during follow-up. Estimated for a person with the following baseline characteristics: 62 years of age, HbA1c of 8.4% (68.3 mmol/mol), diabetes duration of 9.1 years, body weight of 91 kg, body mass index of 32.0 kg/m2 using generalized least squares regression (n = 299 people, n = 889 observations). The coloured lines represent the treatment estimates, while the shaded areas show 95% confidence intervals around the estimated values. ICT, intensified conventional insulin treatment; IDegLira, insulin degludec/liraglutide; IU, insulin unit